 |
|
|
| |
Real-World Outcomes in Patients With Chronic Hepatitis C Virus Infection and Substance Use Disorders Treated With Glecaprevir/Pibrentasvir for 8 Weeks: A Pooled Analysis of Multinational Postmarketing Observational Studies
|
| |
| |
AASLD 2020 Nov 11-16 virtual
Reported by Jules Levin
G Rizzardini1, M Gschwantler2, S Bourgeois3, B Mullhaupt4, W Mazur5, M Bondin6, ZZ Zhang6, F Marra7, E Veitsman8, K Mimidis9, N Marques10, J Foucher1111st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy; 2Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria; 3Stuivenberg ZNA, Antwerp, Belgium; 4Department of Gastroenterology and Hepatology, University Hospital Zurich and University of Zurich, Zurich, Switzerland; 5Clinical Department of Infectious Diseases, Medical University of Silesia, Katowice, Poland; 6AbbVie Inc., North Chicago, Illinois, United States; 7Liver Unit, Rambam Health Care Campus, Haifa, Israel, 8University of Liverpool Hepatology Drug Interactions Group, Liverpool, United Kingdom, 9First Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece; 10Infectious Diseases Service, Hospital Garcia de Orta EPE, Almada, Portugal; 11Hopital du Haut-Leveque, Pessac, France
|
| |
|
|
|
|
|
